Delayed Nyse  -  04:04 2022-06-27 pm EDT
51.88 USD   +0.56%
04:14pSECTOR UPDATE : Health Care Stocks Posting Modest Monday Gains
01:50pSECTOR UPDATE : Health Care Stocks Rising in Defensive Afternoon Trade
11:02aUS grapples with whether to modify COVID vaccine for fall
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Canada approves Pfizer's oral COVID-19 antiviral treatment, deliveries delayed

01/17/2022 | 10:37am EDT
COVID-19 pandemic in Canada

OTTAWA, Jan 17 (Reuters) - Canada on Monday approved Pfizer Inc's oral antiviral treatment for mild to moderate cases of COVID-19 in adults, but said global supply shortages meant only a few doses would be ready now.

Rising infections and hospitalizations due the Omicron variant are forcing provinces to put in restrictions and the federal government to support impacted businesses. Officials predict COVID-19 cases will soar in coming weeks.

"(This approval) is particularly important, as access to easy to use treatments could help to reduce the severity of COVID-19 in adults who become newly infected," chief public health officer Theresa Tam told reporters.

Ottawa said last month it had signed a deal with Pfizer for a million treatment courses, pending approval. A global shortage means only a fraction will arrive soon.

Canada has received 30,400 courses and officials said it will take delivery of another 120,000 by end-March.

"We're among the first countries to have approved the medication but also to have received the medication ... competition is high and we are doing a good job," Federal Health minister Jean-Yves Duclos told a separate briefing.

Pfizer's two-drug antiviral regimen, Paxlovid, was nearly 90% effective in preventing hospitalizations and deaths in patients at high risk of severe illness, according to clinical trial data.

It is meant to be taken at home for five days beginning shortly after onset of symptoms.

Ontario, the most populous of the 10 provinces, is seeing signs Omicron cases may have peaked, chief medical officer Kieran Moore told an Ottawa radio station.

Official data show that as of Jan 8, 87.8% of Canadians aged 12 and older had received two doses of a COVID-19 vaccine.

The U.S. authorized the Pfizer treatment for people ages 12 and older deemed at risk of severe illness last month.

Canada is looking at whether to approve Merck & Co's oral antiviral pill, molnupiravir, which had less impressive results than Paxlovid in its pivotal clinical trial. (Reporting by David Ljunggren in Ottawa and Ismail Shakil in Bengaluru; Editing by Franklin Paul and Bill Berkrot)

© Reuters 2022
All news about PFIZER, INC.
04:14pSECTOR UPDATE : Health Care Stocks Posting Modest Monday Gains
01:50pSECTOR UPDATE : Health Care Stocks Rising in Defensive Afternoon Trade
11:02aUS grapples with whether to modify COVID vaccine for fall
10:43aPfizer Invites Public to View and Listen to Webcast of July 28 Conference Call with Ana..
10:42aPfizer and BioNTech Announce Omicron-Adapted COVID-19 Vaccine Candidates Demonstrate Hi..
08:22aPFIZER INC : Barclays reiterates its Neutral rating
05:44aPfizer-BioNTech COVID-19 Adapted Vaccines Show Higher Immune Response Against Omicron i..
02:09aWill the Court require me to vaccinate my child against COVID-19?
06/26Pfizer-BioNTech's Two Omicron-specific Vaccines Trigger High Immune Response Against CO..
06/25Pfizer says tweaked COVID-19 shots boost omicron protection
More news
Analyst Recommendations on PFIZER, INC.
More recommendations
Financials (USD)
Sales 2022 104 B - -
Net income 2022 35 924 M - -
Net cash 2022 12 888 M - -
P/E ratio 2022 8,63x
Yield 2022 3,13%
Capitalization 291 B 291 B -
EV / Sales 2022 2,68x
EV / Sales 2023 3,44x
Nbr of Employees 79 000
Free-Float 59,0%
Duration : Period :
Pfizer, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PFIZER, INC.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 22
Last Close Price 51,88 $
Average target price 57,26 $
Spread / Average Target 10,4%
EPS Revisions
Managers and Directors
Albert Bourla Chairman, Chief Executive & Operating Officer
David M. Denton Chief Financial Officer & Executive Vice President
Mikael Dolsten Executive VP, President-Research & Development
Lidia L. Fonseca Executive VP, Chief Digital & Technology Officer
Aida Habtezion Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
PFIZER, INC.-12.63%289 466